title: Development of a new medium useful for the recovery of dermatophytes from clinical specimens by minimizing the carryover effect of antifungal agents.
abstract: Two surface-active compounds, egg lecithin and polysorbate 80, usually used as the deactivators of various preservatives were tested whether they also counteract either or all of the three major topical antifungal drugs, bifonazole (BFZ), lanoconazole (LCZ) and terbinafine (TBF). Both egg lecithin and polysorbate 80, when added to culture media up to final concentrations of 1.0 and 0.7%, respectively, antagonized the anti-dermatophytic activity of the three drugs in a concentration-dependent manner. A greater extent of antagonistic action was exerted when the two deactivators combined at their maximal levels tested were added; MIC's of BFZ were increased more than 30-fold and those of LCZ and TBF more than 200-fold compared with the values obtained in the absence of the deactivators. Using the agar medium supplemented with the combined deactivators, culture studies were carried out with skin tissues specimens taken from guinea pigs whose feet were infected with dermatophytes and subsequently treated with 1% topical preparations of the three antifungal drugs. The experimental data from this animal study demonstrated that the combined deactivators-supplemented medium yielded increased numbers of fungi compared with the basal medium. It looks, therefore, likely that the fungal recovery on the former medium more correctly reflects to actual fungal burden in the infected lesions than the latter. All these results suggest that the combined deactivators-supplemented medium is more useful for mycological evaluation of therapeutic efficacy of imidazole and allylamine drugs against dermatophytoses in both preclinical and clinical studies.
authors.affiliation: Pharmaceutical R&D Laboratories, POLA Chemical Industries, Inc., Yokohama, Kanagawa, Japan. takuji@pola.co.jp
authors.forename: Takuji
authors.initials: T
authors.lastname: Nakashima
authors.forename: Akira
authors.initials: A
authors.lastname: Nozawa
authors.forename: Takao
authors.initials: T
authors.lastname: Ito
authors.forename: Toshiro
authors.initials: T
authors.lastname: Majima
authors.forename: Hideyo
authors.initials: H
authors.lastname: Yamaguchi
mesh_terms: D000287:Administration, Topical; D000362:Agar; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D003470:Culture Media; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D006571:Heterocyclic Compounds / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D007093:Imidazoles / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D008828:Microbiological Techniques / Q000379:methods*; D009281:Naphthalenes / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D010713:Phosphatidylcholines; D011136:Polysorbates; D013501:Surface-Active Agents; D000077291:Terbinafine; D014008:Tinea Pedis / Q000188:drug therapy / Q000382:microbiology*; D014249:Trichophyton / Q000302:isolation & purification*
chemical_list: D000935:Antifungal Agents; D003470:Culture Media; D006571:Heterocyclic Compounds; D007093:Imidazoles; D009281:Naphthalenes; D010713:Phosphatidylcholines; D011136:Polysorbates; D013501:Surface-Active Agents; C072774:latoconazole; D000362:Agar; D000077291:Terbinafine; C036596:bifonazole